The FDA granted Astellas Pharma and Seattle Genetics accelerated approval for Padcev, a first-of-its-kind treatment for adult patients with metastatic urothelial bladder cancer.
Abstract. Biliary tract cancers (BTCs) are a heterogeneous group of tumors arising from cells in the bile ducts and gallbladder. The 5-year overall surviva
AbstractBackground. Given the intensive resources required to conduct economic analyses in clinical trials, a key need is identifying scalable measures of
AbstractBackground. Trifluridine-tipiracil (TAS-102) is approved as monotherapy and in combination with bevacizumab for refractory unresectable metastatic
AbstractBackground. The parasympathetic branch of the autonomic nervous system has shown tumor-suppressive effects in preclinical models of pancreatic aden
AbstractBackground. FGFR alterations are known to be driver alterations in several tumor types. We aimed to assess the efficacy of pemigatinib, an oral FGF
AbstractObjectives. Fatigue is a common nonhematologic toxicity of the CDK4/6 inhibitor palbociclib in metastatic breast cancer (MBC) patients with prevale
AbstractBackground. BRCA1/2 genes play a critical role in genome stability and DNA repair. In animal models, loss of cardiomyocyte-specific BRCA1/2 is asso
This article focuses on whether breast cancer characteristics and outcomes differ by race and ethnicity in Canada.
The development of immune-related adverse events (irAEs) has been associated with improved survival outcomes in non-small cell lung cancer (NSCLC). This st
This study focused on a prospective cost analysis conducted at a high-specialty health facility to assess the economic implications of implementing a risk-
